Aflorix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aflorix

Quick Facts

Property Description
Active ingredient Clotrimazole (INN)
Form Topical Preparations (e.g., Cream, Solution)
Pharmacological class Antifungal Drug, Azole Antimycotic Agent
Common use Combating superficial fungal infections (Mycoses)
Origin Synthetic Compound (Imidazole Derivative)

The Identity of Aflorix: A Clinically Recognized Antifungal Agent

Aflorix is a monosemic pharmaceutical preparation whose identity is entirely based on its active ingredient, Clotrimazole (INN). This substance firmly establishes the medicine within the antifungal drug class, specifically categorizing it as an azole antimycotic agent. This classification is clinically recognized for targeting a broad range of dermatophytes and yeasts. The drug’s designation as a broad-spectrum antimycotic agent confirms its primary purpose: providing essential, direct therapeutic action against the fungal pathogens responsible for superficial mycoses.

Composition, Origin, and Topical Differentiation

The core component of Aflorix is the synthetic organic compound Clotrimazole, which is chemically structured as an imidazole derivative. This synthetic origin ensures reliable potency and consistency, distinguishing it from less chemically defined treatments. Aflorix is formatted exclusively as a topical pharmaceutical preparation, intended for application to the surface of the skin or mucous membranes; common forms include creams or solutions. This external route of administration is key to its design, allowing for the delivery of high local concentrations of the active ingredient directly to the site of fungal activity.

The General Mechanism and Purpose of Clotrimazole

Clotrimazole works by achieving a dual antifungal effect: it is both fungistatic (it arrests the growth and replication of the fungus) and, at effective concentrations, fungicidal (it actively eliminates the fungal cells). This action is rooted in its ability to cause targeted membrane disruption by interfering with the synthesis of ergosterol, a crucial structural lipid unique to the fungal cell wall. This mechanism is fundamental to the drug’s effectiveness, allowing it to clear the fungal pathogens and promote the restoration of the affected topical area to health.

Regulatory References

  1. NIH StatPearls: Clotrimazole classification and use

What side effects are possible with Aflorix?

Possible Side Effects and Safety Information

The safety profile of Aflorix, based on its active ingredient Clotrimazole, is characterized by a low incidence of systemic effects due to minimal systemic absorption following topical application. The adverse reactions documented in regulatory sources predominantly affect the application site and are classified as local cutaneous reactions.


Documented Adverse Reactions

The majority of side effects are confined to the Skin and Subcutaneous Tissue Disorders category. These reactions are often classified as Common or Frequency Not Defined in official labeling:

  • Local Cutaneous Reactions: Burning, stinging, erythema (redness), pruritus (itching), blistering, peeling, edema (swelling), urticaria (hives), and general skin irritation.

Serious Adverse Reactions and Systemic Risk

Although rare, the possibility of serious systemic allergic reactions is documented under the Immune System Disorders category. These rare events include anaphylaxis and angioedema (swelling beneath the skin). The minimal systemic absorption of the active ingredient underlies the low reported frequency of these non-local effects.


Safety Considerations

Official regulatory documents include specific constraints regarding the use of Aflorix:

  • Hypersensitivity: The medicine is contraindicated in individuals with a known hypersensitivity to Clotrimazole or any component of the topical preparation.
  • Contraceptive Interaction: Regulatory safety information notes that the medicine may cause damage to latex contraceptives (such as condoms or diaphragms), potentially reducing their effectiveness.

Safety notes are also provided for sensitive populations. For pregnancy, the drug is classified as Category B, indicating harmful effects are not predicted due to minimal systemic exposure, but use should remain under medical oversight. For nursing mothers, it is officially not known if the drug is excreted into human milk.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope (Regulatory Assessment)

Overdosage following the topical application of Aflorix is not expected to lead to acute intoxication. Official regulatory classification holds that acute poisoning is unlikely to occur from routine dermal use due to the minimal systemic absorption of the active ingredient. The sole overdose scenario detailed in official documents is accidental oral ingestion of the product.

Documented Manifestations and Management

If Aflorix is accidentally swallowed, symptoms documented in regulatory labeling may include dizziness, nausea, and vomiting. Official records confirm that no specific antidote is known for the active ingredient. Management for accidental ingestion is directed toward symptomatic and supportive treatment. Procedural interventions, such as gastric lavage, are described as rarely required and are only considered if a life-threatening amount was ingested or if severe clinical signs become apparent within the preceding hour. Official documents also note that if gastric lavage is considered, the airway must be protected adequately.

Urgent Help-Seeking Requirements

The official regulatory guidance mandates that patients or caregivers seek immediate medical attention and contact a Poison Control Center immediately upon any known or suspected accidental oral ingestion. This requirement is due to the potential for systemic effects from a large dose and the lack of a specific counteracting agent to reverse the substance's effects.

Therapeutic Uses of Aflorix

Aflorix is relevant in contexts involving heightened systemic burden, applied across domains where additional symptomatic support is needed, focusing on easing symptoms related to physical discomfort, inflammation, and systemic imbalance. This relevance extends to managing symptoms related to physical discomfort associated with various common conditions.

Aflorix is primarily relevant for easing symptoms such as headaches, muscle aches and sprains, joint tenderness, and fever associated with acute or episodic changes. The medication is applied during phases when the patient experiences heightened discomfort, providing supportive relief when symptoms interfere with routine activities.

“Aflorix may assist with managing symptoms related to inflammatory or irritative states and contributes to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relevance for Symptoms that create noticeable physiological strain

The use of Aflorix supports general well-being and helps maintain a sense of stability when symptoms become more noticeable, particularly in conditions presenting with acute episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information for Ibuprofen

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Aflorix — Official Regulatory Information


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and children 2 years of age and older (safety and effectiveness are established for topical use) [Source 1.1].
Populations for whom use is not recommended Children under 2 years of age, unless directed by a health care provider [Source 1.4].
Populations for whom use is contraindicated Individuals with known hypersensitivity to clotrimazole or to any of the preparation’s components [Source 2.9].
Age-related eligibility rules Use is established in pediatric patients ge 2 years. Use in infants <2 years is not recommended without medical direction [Source 1.1, 1.4].
Pregnancy and lactation eligibility status Pregnancy: Use is preferably avoided in the first trimester; use in later trimesters is permitted under the supervision of a physician or midwife [Source 1.3, 1.10].
Pregnancy and lactation eligibility status Lactation: Use is permitted; however, caution should be exercised as it is not known whether the drug is excreted in human milk [Source 1.3, 1.10].
Eligibility-related restrictions Latex Contraceptives: The product may reduce the effectiveness of latex products (e.g., condoms, diaphragms) when applied to the genital area. Alternative precautions are required [Source 1.10].

Eligibility Classifications (High-Level)

Category Regulatory Statement / Classification
Eligibility severity classification Contraindication: Hypersensitivity to components or drug [Source 2.9]. Restriction/Caution: First Trimester of Pregnancy, Use <2 Years [Source 1.3, 1.4].
Regulatory basis Information based on FDA Prescribing Information/DailyMed and EMA-affiliated Summary of Product Characteristics (SmPC) guidelines [Source 1.3, 1.10].
Eligibility-context constraints External Use Only; Not effective for treatment of nail or scalp infections [Source 1.7].

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with a history of hypersensitivity to clotrimazole or any ingredient in the preparation.
  • Safety and efficacy are established for topical use in children aged two years and older.
  • Use is not recommended in children under two years of age unless directed by a healthcare professional.
  • During pregnancy, use is preferably avoided in the first trimester and is otherwise subject to medical supervision.
  • The medicine may reduce the effectiveness of latex barrier contraceptives when used on the genital area, requiring alternative precautions.

Connection to the overall eligibility profile: Official regulatory documents define the eligibility for Aflorix primarily through absolute contraindications related to patient hypersensitivity and conditional restrictions based on age and reproductive status. Due to minimal systemic absorption, the labeling does not contain eligibility limitations concerning major systemic organ function, such as severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Aflorix (Clotrimazole Topical Preparation) is characterized by minimal systemic interaction risk due to its low absorption through the skin, as documented by regulatory authorities. Consequently, the product is associated with no documented risk of metabolic or transporter-mediated drug-drug interactions with the majority of co-administered systemic medicines.


Documented Interaction Patterns

The most specific interaction warnings documented in prescribing information relate to local effects and related routes of administration.

  • Local Pharmacodynamic Antagonism: Aflorix may reduce the efficacy of other topically applied antifungal agents, specifically polyene antibiotics such as Nystatin, when co-administered locally.

  • Pharmacokinetic Interaction Risk: Official labeling acknowledges the potential for a pharmacokinetic interaction where Clotrimazole may increase the plasma levels of oral Tacrolimus through the inhibition of the CYP3A4 enzyme. This is a crucial consideration noted in the context of the related vaginal route, which has higher local exposure.

  • Product-Substance Restriction: Due to the risk of damage, Aflorix preparations are officially restricted from direct contact with latex barrier contraceptives (condoms, diaphragms). Alternative contraceptive methods are required for a period of at least five days following treatment to avoid reduced effectiveness.

There are no known interactions documented in regulatory summaries between topical Clotrimazole and food, alcohol, or herbal products.

Mechanism of Action

Aflorix (Clotrimazole) exerts its action through a selective mechanism that interferes with the structural integrity and proliferation of fungal pathogens. This action is defined by its selective interference with the cell's essential structural components.

Molecular Inhibition of Fungal Sterol Synthesis

The drug's primary mechanism involves the inhibition of the key fungal enzyme, Lanosterol 14-alpha-demethylase (CYP51). This enzyme is required to synthesize ergosterol, the vital structural component of the fungal cell membrane. By binding to this target, Aflorix prevents the creation of new, functional cell membrane material.


Cascade of Membrane Destabilization and Pathogen Elimination

The enzyme blockade initiates a cascade where the fungal cell is starved of ergosterol and simultaneously forced to incorporate toxic, methylated sterol precursors into its membrane. This dual action profoundly destabilizes the fungal cell's structural integrity and permeability, consequently leading to the leakage of internal contents and, subsequently, the cessation of fungal growth (fungistasis) or complete cell death (fungicidal effect) at high local concentrations.


Physiological Constraint of Local Penetration

The effectiveness of this mechanism is dependent on achieving and maintaining high local concentrations of the drug directly at the pathogen site. This concentration requirement means the mechanism can be physically constrained in tissues that are difficult to penetrate, such as highly keratinized structures, reducing the likelihood of achieving fungicidal concentrations deep within the tissue.

Dosage and Administration Information

How to Use Aflorix

The following details describe the standard administration parameters for Aflorix (Clotrimazole 1% topical preparations).


Administration Protocol

The usage of Aflorix is defined by its Topical route, delivering the 1% concentration of Clotrimazole directly to the dermal site.

Category Official Administration Guideline
Route and Forms Dermal (Topical) using the 1% Cream or 1% Solution
Dosing Schedule Application of a thin layer to the affected and surrounding area
Frequency Used twice daily (typically morning and evening)
Preparation The treatment area must be washed and dried thoroughly before application

Treatment Duration and Specific Conditions

Usage over time is specific to the type of infection being addressed, requiring continuous application to ensure the full therapeutic course. For tinea pedis (athlete’s foot) and tinea corporis (ringworm), the typical course duration is four weeks. For tinea cruris (jock itch), the course is typically completed within two weeks. Regardless of the initial duration, application must continue for a period of at least two weeks after visible signs of the infection have cleared to help prevent recurrence.

Age-Group Administration: The standard adult regimen is applicable to children aged 2 years and older. Use in children under 2 years of age is subject to professional determination.

Application Constraints: Aflorix is not intended for application to the eyes (ophthalmic use) and is not effective for treating infections on the scalp or nails.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aflorix (Topical Clotrimazole)


Evidence for Use in Tinea Corporis (Ringworm)

The research into Aflorix for ringworm (Tinea Corporis) primarily involved short-term, randomized controlled trials (RCTs). Studies included populations of adults and children with mycologically confirmed infections. Research monitored parameters related to physical discomfort and outcomes reflecting daily functioning, specifically monitoring the change in observable signs and the laboratory confirmation of mycological cure (clearance of the fungus).

Studies reported measurements of mycological clearance and symptom reduction over short-term treatment durations, typically spanning 2 to 4 weeks. Findings describe patterns observed in the studies regarding how symptoms evolved in the observed populations and documented the changes measured during the study period within the controlled settings of the trials.


Evidence for Use in Tinea Pedis and Tinea Cruris (Athlete's Foot and Jock Itch)

Aflorix was evaluated in controlled clinical trials, often double-blind, for the conditions marked by functional limitations associated with athlete's foot (Tinea Pedis) and jock itch (Tinea Cruris). Study populations commonly included adults, and sometimes children, with confirmed infections of the feet and groin. Research monitored parameters related to inflammatory or irritative states, including the rate of mycological cure and the degree of change in clinical signs like scaling, fissures, or irritation.

Trial reports documented the proportion of participants who achieved a combined clinical and mycological outcome at the end of the treatment period. Findings indicate that measured symptom resolution was tracked over defined time intervals, typically 4 to 6 weeks for foot infections and 2 to 4 weeks for groin infections.


What Is Still Uncertain About Aflorix Research

Research contributes to the broader evidence landscape, but several limitations remain in the existing data. Sample sizes were modest in many of the foundational studies, and follow-up durations were limited, meaning long-term effects are not fully established across all indications.

Long-term effects are not fully established concerning recurrence rates over extended observation periods for these conditions. The available comparative evidence is limited. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The existing evidence highlights what is known — and what is still uncertain — about Aflorix.

Key Studies & References

  1. Efficacy of Topical Antifungal Agents for Treating Tinea Pedis (Athlete's Foot) in Children: A Systematic Review
  2. Treatment of Cutaneous Candidiasis: A Review of Clinical Evidence

Frequently Asked Questions (FAQ)

Common questions about Aflorix (FAQ)


Q: Is Aflorix considered a prescription medication or is it sold over-the-counter?

Topical Clotrimazole 1% preparations are available in both prescription (Rx) and nonprescription (over-the-counter or OTC) forms. The regulatory classification often depends on the specific form, strength, and indication for which the product is being used. Official labeling confirms that both categories exist for the active ingredient.


Q: Is Aflorix known to cause weight gain or loss?

According to official regulatory adverse reaction reports, weight changes are not commonly associated with topical Clotrimazole. This is due to the medicine's minimal systemic absorption, meaning only a very small amount of the drug enters the bloodstream. Weight changes are typically associated with medications that are absorbed systemically.


Q: Can Aflorix affect my sleep schedule or energy levels?

Regulatory adverse reaction documents do not commonly list effects on the central nervous system, such as changes to sleep or energy levels. Because the drug is applied topically to the skin and is only minimally absorbed into the body, it is generally not reported to cause these types of systemic effects.


Q: Is it normal to feel a mild stomach upset when starting Aflorix?

The documented side effects for Aflorix are primarily local reactions confined to the skin, such as burning, itching, or stinging at the application site. Systemic effects like stomach upset are not commonly reported in the official adverse reaction lists. This is consistent with the drug’s minimal absorption through the skin.


Q: What happens if I accidentally miss taking Aflorix for a day?

Official patient instructions advise application as soon as the dose is remembered. If it is nearly time for the next scheduled dose, however, instructions state that the missed dose is skipped entirely. The label advises against using extra medicine to attempt to make up for a missed application.


Q: Is Aflorix safe for older adults to use?

Regulatory documents do not contain specific clinical information comparing the use of Aflorix in the elderly with other adult age groups. However, the medicine is generally not reported to cause different side effects or problems in older adults than in younger adults, as its effect is primarily local on the skin.


Q: Is Aflorix a narcotic or a controlled substance?

Official classification information confirms that topical Clotrimazole is not designated as a controlled substance by regulatory agencies. It is an antifungal medicine intended for external use only.


Q: Does Aflorix affect how other prescription medicines are absorbed?

Since Aflorix is applied topically and is minimally absorbed into the body’s system, it is reported to be unlikely to significantly affect the absorption of most other prescription medicines taken by mouth. The risk for systemic drug-drug interactions is low due to this minimal absorption.


Q: Do I need a follow-up appointment with my doctor after starting Aflorix?

Regulatory labels specify that a healthcare professional is notified if the treated area shows no improvement after a specific course duration, or if signs of irritation increase. This is the condition under which regulatory labels specify consulting a provider.


Q: What should I do if I notice a change in how Aflorix is affecting me?

Regulatory patient warnings describe stopping use of the treatment if irritation, sensitivity, or increased symptoms (like redness, itching, or blistering) develop at the application site. Official instructions specify informing a healthcare professional.


Q: Does taking Aflorix require any special monitoring or testing?

For patients who do not see clinical improvement, the regulatory label advises that appropriate microbiological studies should be repeated to confirm the diagnosis. This testing helps rule out other pathogens before instituting a different course of antimycotic therapy.


Q: Are there any common over-the-counter pain relievers that interact with Aflorix?

Due to the minimal absorption of the topical drug into the body's system, official regulatory summaries do not list known interactions between Aflorix and common over-the-counter pain relievers.


Q: Why is Aflorix sometimes mentioned in connection with gut health?

Aflorix, containing topical Clotrimazole, is specifically indicated and designed only for external use on the skin. Because it is minimally absorbed into the body, official information confirms it is not intended or indicated to treat conditions related to gut health.


Q: What does the box warning or 'Black Box Warning' (if applicable) say about Aflorix?

The official regulatory labeling provided by government agencies for topical Clotrimazole does not contain a Boxed Warning, which is often referred to as a Black Box Warning.


Q: Does Aflorix affect kidney function?

Because Aflorix is minimally absorbed when applied to the skin, there are typically no specific warnings or restrictions concerning kidney function included in the regulatory labeling for the topical product.


Q: Do regulatory agencies list any potential drug-disease interactions for Aflorix?

Regulatory documents reflect the minimal systemic absorption of the topical form, meaning that major drug-disease interactions are generally not listed. However, a related oral form of the drug does carry a moderate potential hazard for patients with liver impairment.

How should Aflorix be stored and disposed of?

The storage and disposal of Aflorix (Clotrimazole topical) must strictly adhere to instructions provided in government regulatory labeling to maintain the product's integrity.

Storage & Disposal Scope

Element Official Regulatory Requirement
Labeled storage temperature requirements Store at Controlled Room Temperature, generally defined as 20 C to 25 C (68 F to 77 F).
Light/moisture protection requirements Store away from direct light, excess heat, and moisture; do not store in a bathroom.
Handling requirements Keep from freezing (do not freeze); keep in the original container and tightly closed.
Child-protection storage requirements Must be stored out of the sight and reach of children and pets.
Disposal instructions Dispose of unused or expired product in accordance with local requirements; utilize drug take-back programs if available.

Official Storage and Disposal Statements

Regulatory documents mandate that the product is stored at Controlled Room Temperature and protected from freezing, light, and excess heat or moisture. The medicine must remain in the original, tightly closed container and be kept out of the reach of children. Disposal of any unused or expired product must be managed via local regulatory channels or designated take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aflorix found in:

A-Z Index: